Baxter International (BAX) is one of the biggest firms in the injectable therapies business, manufacturing everything from IV bags and solutions to dialysis equipment. In short, if it involves a needle, Baxter is probably involved somewhere in the supply chain -- or it would be if the business looked lucrative enough.
Baxter isn't interested in many of the broad injectables that other pharmaceutical and medical device firms focus on. Instead, the firm's niche positioning has paved the road to exemplary profitability by keeping Baxter's eye on disorders like hemophilia.>>5 Technical Trades Under $10 Baxter's BioScience segment has been successful at innovating its way to bigger revenues over the last several decades, even if that strategy comes with higher risks than a more reactionary pharma firm takes on. After all, with higher risks come higher rewards. While the firm's pharma arm is focused on niche offerings, its medical device segment is more interested in being a generalist. The firm supplies consumables as well as some more specialized devices (dialysis machines, for instance) to patients and healthcare facilities around the world. Those businesses don't have the same moat as its therapies do, but they provide a more consistent recurring revenue stream for investors. With rising analyst sentiment in BAX this week, we're betting on shares.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV